Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 123, Issue 2, 2010, Pages 427-435

  Lobo, Christopher ^a   Lopes, Gilberto ^b,c   Baez, Odalys ^d   Castrellon, Aurelio ^d   Ferrell, Annapoorna ^d   Higgins, Connie ^d   Hurley, Erin ^d   Hurley, Judith ^d   Reis, Isildinha ^d   Richman, Stephen ^d   Seo, Pearl ^d   Silva, Orlando ^d   Slingerland, Joyce ^d   Tukia, Keleni ^d   Welsh, Catherine ^d   Glück, Stefan ^d  

^a Florida Eye Specialist Institute   (United States)

^b Johns Hopkins Singapore   (Singapore)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bevacizumab; First line therapy; Gemcitabine; HER2 negative metastatic breast cancer; Nab paclitaxel

Indexed keywords

ALBUMIN; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NANOPARTICLE; PACLITAXEL;

ABSCESS; ACUTE KIDNEY FAILURE; ADULT; AGED; ALOPECIA; AMENORRHEA; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; BLURRED VISION; BONE PAIN; BREAST ABSCESS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; COUGHING; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSGEUSIA; DYSPNEA; EDEMA; EPIGASTRIC PAIN; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLU LIKE SYNDROME; FOOT EDEMA; GASTROESOPHAGEAL REFLUX; HAND FOOT SYNDROME; HEADACHE; HEART TAMPONADE; HEART VALVE REGURGITATION; HEARTBURN; HEAT INTOLERANCE; HEMATURIA; HOT FLUSH; HUMAN; HYPERTENSION; INSOMNIA; JAUNDICE; LEUKOPENIA; LYMPHEDEMA; MALE; METASTASIS; MOUTH INFECTION; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PELVIS PAIN SYNDROME; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RHINORRHEA; SCOTOMA; SEIZURE; SEPSIS; SIDE EFFECT; SKIN DEFECT; SKIN DISCOLORATION; SURVIVAL RATE; SYNCOPE; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; THROMBUS; TRICUSPID VALVE REGURGITATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ALBUMINS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLORIDA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956184020     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1002-0     Document Type: Article

References (23)

1. American Cancer Society (2009) Breast cancer facts and figures 2009. American Cancer Society Inc, Atlanta
2. J O'Shaughnessy 2005 Extending survival with chemotherapy in metastatic breast cancer Oncologist 10 suppl 3 20 29 10.1634/theoncologist.10-90003-20 16368868
3. EL Mayer HJ Burstein 2007 Chemotherapy for metastatic breast cancer Hematol Oncol Clin North Am 21 257 272 10.1016/j.hoc.2007.03.001 17512448
4. WJ Gradishar S Tjulandin N Davidson H Shaw N Desia P Bhar, et al.. 2005 Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 31 7794 7803 10.1200/JCO.2005.04.937 1:CAS:528:DC%2BD2MXht1Cqs7nK 16172456
5. WJ Gradishar D Krasnojon S Cheporov AN Makhson G Manikhas A Clawson, et al.. 2009 Significantly longer progression-free survival with nab-Paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer J Clin Oncol 27 3611 3619 10.1200/JCO.2008.18.5397 1:CAS:528:DC%2BD1MXhtVOnu7nE 19470941
6. S Tomao A Romiti F Tamao M Di Seri G Caprio GP Spinelli, et al.. 2006 A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer BMC Cancer 6 137 10.1186/1471-2407-6-137 16723016
7. KS Albain SM Nag G Calderillo-Ruiz JP Jordaan AC Llombart A Pluzanska, et al.. 2008 Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment J Clin Oncol 26 3950 3957 10.1200/JCO.2007.11.9362 18711184
8. K Miller M Wang J Gralow M Dickler M Cobleigh E Perez, et al.. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 10.1056/NEJMoa072113 1:CAS:528: DC%2BD1cXisVOnsg%3D%3D 18160686
9. R Gray S Bhattacharya C Bowden K Miller R Comis 2009 Independent Review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer J Clin Oncol 27 4966 4972 10.1200/JCO.2008.21.6630 1:CAS:528:DC%2BD1MXhsVCrsr%2FJ 19720913
10. MA Danso JL Blum NJ Robert L Krekow R Rotche DA Smith, et al.. 2008 Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer J Clin Oncol 26 suppl 1075
11. TM) in combination with bevacizumab with or without gemcitabine: Early experience at the University of Miami/Braman Family Breast Cancer Institute Biomed Pharmacother 61 531 533 10.1016/j.biopha.2007.08.008 1:CAS:528:DC%2BD2sXhtF2ru7zJ 17913443
12. Collett D (2003) Modeling survival data in medical research. Chapman & Hill, London
13. AK Conlin CA Hudis A Bach M Moynahan D Lake A Forero-Torres, et al.. 2009 Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer J Clin Oncol 27 Suppl 1006
14. G Bonadonna E Brusamolino P Valagussa A Rossi L Brugnatelli C Brambilla, et al.. 1976 Combination chemotherapy as an adjuvant treatment in operable breast cancer N Engl J Med 294 405 410 10.1056/NEJM197602192940801 1:STN:280:DyaE287gtVKrtA%3D%3D 1246307
15. GW Sledge D Neuberg JN Bernardo JN Ingle S Martino EK Rowinsky, et al.. 2003 Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup Trial (E1193) J Clin Oncol 21 4 588 592 10.1200/JCO.2003.08.013 12586793
16. O'Shaughnessy JA, Blum JL, Sandbach JF, Savin M, Fenske E, and Hawkins MJ (2004) Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. Paper presented at the 27th Annual San Antonio Breast Cancer Symposium; 2004 December 8-11, San Antonio (TX). Abstract1070
17. KD Miller LI Chap FA Holmes MA Cobleigh PK Marcom L Fehrenbacher, et al.. 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 792 799 10.1200/JCO.2005.05.098 1:CAS:528:DC%2BD2MXitVKitrk%3D 15681523
18. NK Ibrahim N Desai S Legha P Soon-Shiong RL Theriault E Rivera, et al.. 2002 Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin Cancer Res 8 5 1038 1044 1:CAS:528:DC%2BD38XksVSqurg%3D 12006516
19. N Robert B Leyland-Jones L Asmar R Belt D Ilegbodu D Loesch, et al.. 2006 Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer J Clin Oncol 24 2786 2792 10.1200/JCO.2005.04.1764 1:CAS:528:DC%2BD28XntV2hu7g%3D 16782917
20. Northfelt DW (2008) Paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine, and bevacizumab in treating patients with metastatic breast cancer. 2008 Clinicaltrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00662129?term=NCT00662129&rank=1. Assessed 28 Jan 2010
21. Sledge GW, Miller K, Moisa C, Gradishar W (2007) Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. Paper presented at the 2007 ASCO Annual Meeting; 2007 June 1-5, Chicago (IL). Abstract 1013
22. G Colon-Otero RC Smallridge LA Solberg TD Keith TA Woodward FB Willis, et al.. 2008 Disparities in participation in cancer clinical trials in the United States Cancer 112 3 447 454 10.1002/cncr.23201 18085590
23. VH Murthy HM Krumholz CP Gross 2004 Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities JAMA 291 22 2720 2726 10.1001/jama.291.22.2720 1:CAS:528:DC%2BD2cXkvVeqsL4%3D 15187053